Wellmark

Does Wellmark cover Ozempic?

Quick answer · Type 2 Diabetes

Wellmark covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered (preferred drug). A1C of 6.5% or higher
  • ACA Marketplace: Covered (preferred drug). A1C of 6.5% or higher

Last verified June 3, 2026. Policy effective March 17, 2026. Source: Antidiabetic-GLP-1-Receptor-Agonists-and-GIP-GLP-1-Receptor-Agonists.pdf. How we verify this data →

Check your card for your exact plan →

Ozempic for Type 2 Diabetes

What Wellmark requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Diagnosis documented with a code
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Auto-adjudication via claims history

All of:

  • ICD-10 diagnosis code for type 2 diabetes mellitus present in member's medical claims history

Prior authorization — confirmed T2DM diagnosis

Plus any one of:

  • History of A1C >= 6.5%
  • History of 2-hour plasma glucose >= 200 mg/dL during OGTT
  • History of symptoms of hyperglycemia (polyuria, polydipsia, polyphagia) or hyperglycemic crisis AND random plasma glucose >= 200 mg/dL
  • History of fasting plasma glucose (FPG) >= 126 mg/dL

Documentation to bring

  • Chart notes or medical record documentation supporting a diagnosis of type 2 diabetes mellitus (A1C > 6.5%, 2-hour plasma glucose >= 200 mg/dL during OGTT, symptoms of hyperglycemia with random plasma glucose >= 200 mg/dL, or fasting plasma glucose >= 126 mg/dL)

Quantity limits

  • injection — all strengths — 1 pen/28 days
  • tablet — all strengths — 30 tablets/30 days

Approval and renewal

  • Initial approval: 12 months

Not covered when

  • Weight reduction/management use is a standard exclusion for most benefits

Policy note: Ozempic (injection) is listed as a preferred product. Ozempic (tablet) is referenced alongside Rybelsus with the same labeling language. The policy uses a screen-out logic: if an ICD-10 code for T2DM is present in claims history, the drug is paid without PA. The FDA-approved indications for Ozempic include CV risk reduction in T2DM with established CVD and CKD, but the policy's coverage criteria only address T2DM and do not establish separate PA criteria for those indications — they are not addressed as standalone criteria in this document. The quantity limit is listed separately for injection (1 pen/28 days) and tablet (30 tablets/30 days).

Policy effective March 17, 2026 · verified June 3, 2026 · source: Antidiabetic-GLP-1-Receptor-Agonists-and-GIP-GLP-1-Receptor-Agonists.pdf

ACA Marketplace

Covered (preferred drug)

What you need to qualify

  • A1C of 6.5% or higher
  • Diagnosis documented with a code
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Auto-adjudication via claims history

All of:

  • ICD-10 diagnosis code for type 2 diabetes mellitus present in member's medical claims history

Prior authorization — confirmed T2DM diagnosis

Plus any one of:

  • History of A1C >= 6.5%
  • History of 2-hour plasma glucose >= 200 mg/dL during OGTT
  • History of symptoms of hyperglycemia (polyuria, polydipsia, polyphagia) or hyperglycemic crisis AND random plasma glucose >= 200 mg/dL
  • History of fasting plasma glucose (FPG) >= 126 mg/dL

Documentation to bring

  • Chart notes or medical record documentation supporting a diagnosis of type 2 diabetes mellitus (A1C > 6.5%, 2-hour plasma glucose >= 200 mg/dL during OGTT, symptoms of hyperglycemia with random plasma glucose >= 200 mg/dL, or fasting plasma glucose >= 126 mg/dL)

Quantity limits

  • injection — all strengths — 1 pen/28 days
  • tablet — all strengths — 30 tablets/30 days

Approval and renewal

  • Initial approval: 12 months

Not covered when

  • Weight reduction/management use is a standard exclusion for most benefits

Policy note: Ozempic (injection) is listed as a preferred product. Ozempic (tablet) is referenced alongside Rybelsus with the same labeling language. The policy uses a screen-out logic: if an ICD-10 code for T2DM is present in claims history, the drug is paid without PA. The FDA-approved indications for Ozempic include CV risk reduction in T2DM with established CVD and CKD, but the policy's coverage criteria only address T2DM and do not establish separate PA criteria for those indications — they are not addressed as standalone criteria in this document. The quantity limit is listed separately for injection (1 pen/28 days) and tablet (30 tablets/30 days).

Policy effective March 17, 2026 · verified June 3, 2026 · source: Antidiabetic-GLP-1-Receptor-Agonists-and-GIP-GLP-1-Receptor-Agonists.pdf

Why Ozempic requests get denied by Wellmark

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Ozempic and Wegovy are the same molecule with different approved uses; a request for Ozempic under a diagnosis that matches Wegovy is routinely denied.
  2. Diagnosis code missing or wrong on the request.
  3. No recent A1C result on file.

Frequently asked questions

Does Wellmark cover Ozempic?
Wellmark covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
How long does a Ozempic approval last with Wellmark?
Initial approvals last 12 months.
How current is this information?
This page reflects Wellmark's written policy as of March 17, 2026, last verified against the source document on June 3, 2026.

Other medications under Wellmark

Ozempic coverage under other plans

All insurance plans · All medications

This page summarizes Wellmark's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.